195 related articles for article (PubMed ID: 15566298)
1. The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase.
Leftheris K; Ahmed G; Chan R; Dyckman AJ; Hussain Z; Ho K; Hynes J; Letourneau J; Li W; Lin S; Metzger A; Moriarty KJ; Riviello C; Shimshock Y; Wen J; Wityak J; Wrobleski ST; Wu H; Wu J; Desai M; Gillooly KM; Lin TH; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Zhang R; Diller D; Doweyko A; Sack J; Baldwin J; Barrish J; Dodd J; Henderson I; Kanner S; Schieven GL; Webb M
J Med Chem; 2004 Dec; 47(25):6283-91. PubMed ID: 15566298
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
[TBL] [Abstract][Full Text] [Related]
3. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors.
Lin TH; Metzger A; Diller DJ; Desai M; Henderson I; Ahmed G; Kimble EF; Quadros E; Webb ML
J Pharmacol Exp Ther; 2006 Aug; 318(2):495-502. PubMed ID: 16702443
[TBL] [Abstract][Full Text] [Related]
4. 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.
Liu C; Wrobleski ST; Lin J; Ahmed G; Metzger A; Wityak J; Gillooly KM; Shuster DJ; McIntyre KW; Pitt S; Shen DR; Zhang RF; Zhang H; Doweyko AM; Diller D; Henderson I; Barrish JC; Dodd JH; Schieven GL; Leftheris K
J Med Chem; 2005 Oct; 48(20):6261-70. PubMed ID: 16190753
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors.
Wrobleski ST; Lin S; Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Gillooly KM; Shuster DJ; McIntyre KW; Doweyko AM; Kish KF; Tredup JA; Duke GJ; Sack JS; McKinnon M; Dodd J; Barrish JC; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2739-44. PubMed ID: 18364256
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases.
Liu C; Lin J; Wrobleski ST; Lin S; Hynes J; Wu H; Dyckman AJ; Li T; Wityak J; Gillooly KM; Pitt S; Shen DR; Zhang RF; McIntyre KW; Salter-Cid L; Shuster DJ; Zhang H; Marathe PH; Doweyko AM; Sack JS; Kiefer SE; Kish KF; Newitt JA; McKinnon M; Dodd JH; Barrish JC; Schieven GL; Leftheris K
J Med Chem; 2010 Sep; 53(18):6629-39. PubMed ID: 20804198
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity.
Ottosen ER; Sørensen MD; Björkling F; Skak-Nielsen T; Fjording MS; Aaes H; Binderup L
J Med Chem; 2003 Dec; 46(26):5651-62. PubMed ID: 14667219
[TBL] [Abstract][Full Text] [Related]
9. Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase.
Cumming JG; McKenzie CL; Bowden SG; Campbell D; Masters DJ; Breed J; Jewsbury PJ
Bioorg Med Chem Lett; 2004 Nov; 14(21):5389-94. PubMed ID: 15454232
[TBL] [Abstract][Full Text] [Related]
10. Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR.
Angell RM; Angell TD; Bamborough P; Brown D; Brown M; Buckton JB; Cockerill SG; Edwards CD; Jones KL; Longstaff T; Smee PA; Smith KJ; Somers DO; Walker AL; Willson M
Bioorg Med Chem Lett; 2008 Jan; 18(1):324-8. PubMed ID: 17981461
[TBL] [Abstract][Full Text] [Related]
11. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
[TBL] [Abstract][Full Text] [Related]
12. 1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase.
Lumeras W; Vidal L; Vidal B; Balagué C; Orellana A; Maldonado M; Domínguez M; Segarra V; Caturla F
J Med Chem; 2011 Nov; 54(22):7899-910. PubMed ID: 21999461
[TBL] [Abstract][Full Text] [Related]
13. Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.
Goldstein DM; Alfredson T; Bertrand J; Browner MF; Clifford K; Dalrymple SA; Dunn J; Freire-Moar J; Harris S; Labadie SS; La Fargue J; Lapierre JM; Larrabee S; Li F; Papp E; McWeeney D; Ramesha C; Roberts R; Rotstein D; San Pablo B; Sjogren EB; So OY; Talamas FX; Tao W; Trejo A; Villasenor A; Welch M; Welch T; Weller P; Whiteley PE; Young K; Zipfel S
J Med Chem; 2006 Mar; 49(5):1562-75. PubMed ID: 16509574
[TBL] [Abstract][Full Text] [Related]
14. Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Buchanan JL; Buckner WH; Cee VJ; Chai L; Deak HL; Epstein LF; Faust T; Gallant P; Geuns-Meyer SD; Gore A; Gu Y; Henkle B; Hodous BL; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; Masse CE; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; White RD; Zhao H; Zhu L; Zhu X
J Med Chem; 2006 Sep; 49(19):5671-86. PubMed ID: 16970394
[TBL] [Abstract][Full Text] [Related]
15. p38 MAP kinase inhibitors. Part 5: discovery of an orally bio-available and highly efficacious compound based on the 7-amino-naphthyridone scaffold.
Natarajan SR; Liu L; Levorse M; Thompson JE; O'Neill EA; O'Keefe SJ; Vora KA; Cvetovich R; Chung JY; Carballo-Jane E; Visco DM
Bioorg Med Chem Lett; 2006 Oct; 16(20):5468-71. PubMed ID: 16945534
[TBL] [Abstract][Full Text] [Related]
16. Optimization of alpha-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Kucharski J; Lum C; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Urban J; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2010 Aug; 20(16):4819-24. PubMed ID: 20663667
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, crystal structure, and activity of pyrazole-based inhibitors of p38 kinase.
Graneto MJ; Kurumbail RG; Vazquez ML; Shieh HS; Pawlitz JL; Williams JM; Stallings WC; Geng L; Naraian AS; Koszyk FJ; Stealey MA; Xu XD; Weier RM; Hanson GJ; Mourey RJ; Compton RP; Mnich SJ; Anderson GD; Monahan JB; Devraj R
J Med Chem; 2007 Nov; 50(23):5712-9. PubMed ID: 17948975
[TBL] [Abstract][Full Text] [Related]
19. A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis.
Brown DS; Belfield AJ; Brown GR; Campbell D; Foubister A; Masters DJ; Pike KG; Snelson WL; Wells SL
Bioorg Med Chem Lett; 2004 Nov; 14(21):5383-7. PubMed ID: 15454231
[TBL] [Abstract][Full Text] [Related]
20. Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode.
Angell RM; Bamborough P; Cleasby A; Cockerill SG; Jones KL; Mooney CJ; Somers DO; Walker AL
Bioorg Med Chem Lett; 2008 Jan; 18(1):318-23. PubMed ID: 18006306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]